Search

Nanomedicine offers tremendous opportunities for the development of novel therapeutic and diagnostic tools. During the last decades, extensive knowledge was gained about stabilizing and the coating of nanoparticles, their functionalization for drug binding and drug release and possible strategies for therapies and diagnostics of different diseases. Most recently, more and more emphasis has been placed on nanotoxicology and nanosafety aspects. The section of experimental oncology and nanomedicine developed a concept for translating this knowledge into clinical application of magnetic drug targeting for the treatment of cancer and other diseases using superparamagnetic iron oxide nanoparticles. This approach includes reproducible synthesis, detailed characterization, nanotoxicological testing, evaluation in ex vivo models, preclinical animal studies and production of superparamagnetic iron oxide nanoparticles according to good manufacturing practice regulations.

The term 'nanomedicine' refers to the use of nanotechnology in the treatment, diagnosis and monitoring of diseases. Magnetic drug targeting is a particularly promising application in this field. The goal of the carrier systems involved is to achieve active enrichment of effective substances in diseased tissue. Numerous nanosystems can be used as carriers, but magnetic iron oxide nanoparticles are particularly important. On the one hand, the particles serve as carriers for the active substance, while on the other hand they can also be visualized using conventional imaging techniques and can therefore be used for 'theranostic' purposes. They can also be used in hyperthermia, another important pillar of nanomedicine. Both procedures are intended to lead to specific forms of treatment, which is of medical and economic relevance in view of the increasing numbers of cancer patients worldwide. This study offers a brief overview of current developments in medical applications for magnetic nanoparticles in cancer therapy.